摘要
目的 分析代谢相关脂肪性肝病(MAFLD)患者有机阴离子转运蛋白1B1(SLCO1B1)和载脂蛋白E(APOE)基因多态性与脂代谢紊乱的关系。方法 2018年8月~2021年8月我院诊治的MAFLD患者121例和同期健康体检者150例,常规检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平,采用PCR-荧光探针法检测外周血SLCO1B1和APOE基因型。结果 MAFLD组血清TC、TG和LDL-C水平分别为(5.8±2.3)mmol/L、(2.9±1.4)mmol/L和(3.3±1.5)mmol/L,均显著高于健康人【分别为(4.8±1.2)mmol/L、(1.5±1.3)mmol/L和(2.6±1.1)mmol/L,P<0.05】;MAFLD组SLCO1B1基因*1a/*1a和*1a/*1b基因型频率分别为8.3%和35.5%,显著高于健康人的2.7%和23.3%(P<0.05),而*1b/*1b基因型频率为32.2%,显著低于健康人的46.0%(P<0.05);MAFLD组APOE基因ε3/3基因型频率和E3基因表型频率分别为69.4%和71.9%,显著高于健康人的56.7%和58.7%(P<0.05),而ε3/4基因型频率和E4基因表型频率分别为17.4%和18.2%,均显著低于健康人的29.3%和30.7%(P<0.05);26例SLCO1B1基因B型患者血清TC、TG和LDL-C水平分别为(6.4±1.2)mmol/L、(3.5±2.2)mmol/L和(3.8±0.8)mmol/L,均显著高于92例A型患者【分别为(5.5±1.3)mmol/L、(2.6±3.3)mmol/L和(3.0±1.2)mmol/L,P<0.05】或3例C型患者【分别为(4.6±0.3)mmol/L、(2.6±0.9)mmol/L和(2.5±0.2)mmol/L,P<0.05】;87例APOE基因E3型血清TG和LDL-C水平分别为(3.2±1.6)mmol/L和(3.4±1.1)mmol/L,显著高于12例E2型【分别为(2.7±1.8)mmol/L和(2.8±0.8)mmol/L,P<0.05】或22例E4型【分别为(2.3±0.7)mmol/L和(3.0±1.2)mmol/L,P<0.05】。结论 MAFLD患者SLCO1B1和APOE基因多态性与脂代谢紊乱密切相关,值得深入研究。
Objective The aim of this study was to explore the gene polymorphisms of solute carrier organic anion transporter family member 1B1(SLCO1B1) and apolipoprotein E(APOE) to lipid metabolism in patients with metabolism-associated fatty liver diseases(MAFLD). Methods 121 patients with MAFLD and 150 healthy persons were encountered in our hospital between August 2018 and August 2021. Peripheral blood total cholesterol(TC), triglyceride(TG), high-density lipoprotein cholesterol(HDL-C) and low-density lipoprotein cholesterol(LDL-C) levels were detected, and SLCO1B1 and APOE gene phenotypes in the two groups were determined. Results Serum TC, TG and LDL-C levels in patients with MAFLD were(5.8±2.3)mmol/L,(2.9±1.4)mmol/L and(3.3±1.5)mmol/L, all significantly higher than [(4.8±1.2)mmol/L,(1.5±1.3)mmol/L and(2.6±1.1)mmol/L, respectively, P<0.05];the frequency of SLCO1B1 genotyp *1a/*1a and *1a/*1b in patients with MAFLD were 8.3% and 35.5%, both significantly higher than 2.7% and 23.3%(P<0.05), while the frequency of phenotype *1b/*1b were 32.2%, significantly lower than 46.0%(P<0.05) in the healthy persons;the frequency of APOE genotype ε3/3 and the frequency of E3 phenotype in patients with MAFLD were 69.4% and 71.9%, both significantly higher than 56.7% and 58.7%(P<0.05), while the frequencies of genotypeε 3/4 and phenotype E4 were 17.4% and 18.2%, both significantly lower than 29.3% and 30.7%(P<0.05) in healthy individuals;serum TC, TG and LDL-C levels in 26 MAFLD patients with SLCO1B1genotype B were(6.4±1.2)mmol/L,(3.5±2.2)mmol/L and(3.8±0.8)mmol/L, all significantly higher than [(5.5±1.3)mmol/L,(2.6±3.3)mmol/L and(3.0±1.2)mmol/L, respectively, P<0.05] in 92 patients with genotype A or [(4.6±0.3)mmol/L,(2.6±0.9)mmol/L and(2.5±0.2)mmol/L, respectively, P<0.05] in 3 patients with genotype C;serum TG and LDL-C levels in 87 patients with APOE genotype E3 were(3.2±1.6)mmol/L and(3.4±1.1)mmol/L, both significantly higher than [(2.7±1.8)mmol/L and(2.8±0.8)mmol/L, respectively, P<0.05] in 12 patients with genotype E2 or [(2.3±0.7)mmol/L and(3.0±1.2)mmol/L, respectively, P<0.05] in 22 patients with genotype E4. Conclusion The gene polymorphisms of SLCO1B1 and APOE in patients with MAFLD are closely related to lipid metabolism disorders, and needs further investigation.
作者
熊印祥
宦丽君
刘巧
Xiong Yinxiang;Huan Lijun;Liu Qiao(Clinical Laboratory,Liyuan Hospital,Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430000,Hubei Province,China)
出处
《实用肝脏病杂志》
CAS
2023年第2期206-209,共4页
Journal of Practical Hepatology
基金
湖北省卫健委科研项目(编号:WJ2019Q037)。
